Stocks · News reference
Reported Earlier, Quantum BioPharma Approves Debt Settlement Of C$123,487.43 Via Class B Shares At Deemed Price Of C$4.26 Or Lower
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 21, 2026, 6:53 AM
- Checked
- Jul 21, 2026, 6:53 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Quantum BioPharma Says FDA Cleared IND For Lucid-MS Phase 2 Trial In Progressive Multiple Sclerosis; Reports Cash Runway To At Least October 2027
Read original at benzingaEXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis Trial
FDA approves Quantum BioPharma's IND application for Lucid-MS, advancing its progressive multiple sclerosis treatment to Phase 2 trials.
Read original at benzingaEXCLUSIVE: FDA Approves Quantum BioPharma's Lucid-MS Phase 2 Trial of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination For Progressive Multiple Sclerosis
Read original at benzinga